{"doi":"10.1111/cen.14309","title":"Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly","abstract":"OBJECTIVE: Acromegaly is associated with impaired quality of life (QoL). We investigated the effects of biochemical control of acromegaly by growth hormone receptor antagonism vs somatostatin analog therapy on QoL. DESIGN: Cross-sectional. PATIENTS: 116 subjects: n = 55 receiving a somatostatin analog (SSA group); n = 29 receiving pegvisomant (PEG group); n = 32 active acromegaly on no medical therapy (ACTIVE group). MEASUREMENTS: Acromegaly QoL Questionnaire (AcroQoL), Rand 36-Item Short Form Survey (SF-36) and Gastrointestinal QoL Index (GIQLI); fasting glucose, insulin and IGF-1 levels (LC/MS, Quest Diagnostics). RESULTS: , and male sex 38%]. Mean IGF-1 Z-scores were higher in ACTIVE (3.9 ± 1.0) vs SSA and PEG, which did not differ from one another (0.5 ± 0.7 and 0.5 ± 0.7, P < .0001 vs ACTIVE). Eighty-three per cent of PEG previously received somatostatin analogs, which had been discontinued due to lack of efficacy (52%) or side effects (41%). There were no differences in the four QoL primary end-points (AcroQoL Global Score, SF-36 Physical Component Summary Score, SF-36 Mental Health Summary Score and GIQLI Global Score) between SSA and PEG. Higher HbA1c, BMI and IGF-1 Z-scores were associated with poorer QoL in several domains. CONCLUSION: Our data support a comparable QoL in patients receiving pegvisomant vs somatostatin analogs, despite the fact that the vast majority receiving pegvisomant did not respond to or were not able to tolerate somatostatin analogs.","journal":"Clinical Endocrinology","year":2020,"id":74461,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9337,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":389857,"name":"Allison Kimball","orcid":"0000-0002-6750-644X","position":1,"is_corresponding":false},{"id":311872,"name":"Kevin C.J. Yuen","orcid":"0000-0002-8169-2728","position":2,"is_corresponding":false},{"id":391360,"name":"Whitney W. Woodmansee","orcid":null,"position":3,"is_corresponding":false},{"id":389858,"name":"Melanie S. Haines","orcid":"0000-0003-1002-4754","position":4,"is_corresponding":false},{"id":391361,"name":"Qiu Guan","orcid":null,"position":5,"is_corresponding":false},{"id":389859,"name":"Brooke Swearingen","orcid":"0000-0003-2945-7912","position":6,"is_corresponding":false},{"id":389860,"name":"Lisa B. Nachtigall","orcid":"0000-0002-5708-5231","position":7,"is_corresponding":false},{"id":282317,"name":"Nicholas A. Tritos","orcid":"0000-0001-8867-607X","position":8,"is_corresponding":false},{"id":391362,"name":"Julie L. Sharpless","orcid":null,"position":9,"is_corresponding":false},{"id":160512,"name":"Ursula B Kaiser","orcid":"0000-0002-8237-0704","position":10,"is_corresponding":false},{"id":391363,"name":"Anu V. Gerweck","orcid":null,"position":11,"is_corresponding":false},{"id":389861,"name":"Karen K. Miller","orcid":"0000-0001-9438-2449","position":12,"is_corresponding":false},{"id":389856,"name":"Laura E. Dichtel","orcid":"0000-0001-6989-2308","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":null,"created_at":"2026-07-18T21:46:11.663457Z","pmid":"32779234","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}